Interventions: Drug: Regorafenib; Biological: Nivolumab; Drug: Docetaxel; Drug: Paclitaxel; Drug: Irinotecan; Drug: Trifluridine/Tipracil
Sponsors: Australasian Gastro-Intestinal Trials Group; Bayer; Bristol-Myers Squibb; University of Sydney; Academic and Community Cancer Research United; Taiwanese Cooperative Oncology Group; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.